Better Personalized Prostate Cancer Treatment In The Offing With New Testing Method

A new diagnostic method being studied to find detect and predict the aggressiveness and relapse of cancer originating from the prostate gland is showing promising result. This test and study is being carried out presently in the University Of Pittsburgh School Of Medicine.

A new formula is developed by the researchers so as to enable medical professionals to predict cancer that will relapse after treatment and also how aggressive it is for the body.

This new study is being supported by Dr David Samadi, one of the best known Urologist and Senior personal at the Popular Mount Sinai Medical Center. Here are more details about this new test for prostate cancer:

World-renowned prostate surgeon, Dr. David Samadi, may soon have the equation he needs to strengthen his approach to personalized medicine and prostate cancer treatment. Researchers at the University of Pittsburgh School of Medicine developed a new prostate cancer diagnostic formula to accurately predict the lifecycle of a man’s prostate cancer.

Beyond confirming the presence of prostate cancer, this new test gives unprecedented insight into the cancer’s aggressiveness and the likelihood of relapse after treatment. By conducting genetic analysis of copy number variations (CNV) in the tumor cells, the cells of the surrounding benign tissue, and the blood cells, experts were able to predict the prostate cancer’s path with as much as 81 percent accuracy.

“This may be the magic mix we need to fully understand prostate cancer once it’s diagnosed,” expressed Dr. Samadi. “Being able to unlock the aggressiveness of each unique diagnosis and then tailor surgery and other treatments accordingly will elevate how we eradicate prostate cancer exponentially.”

The prostate specific antigen (PSA) blood test and follow-up biopsy receive ongoing scrutiny for their diagnostic limitations. Despite even the government poking holes in these tests, Dr. Samadi remains a steadfast proponent of their effectiveness. “The PSA test and the biopsy are the best prostate cancer indicators we have today,” said Dr. Samadi. “As an expert, my job is to educate men about their disease and offer the most personalized and effective care possible.”

As Vice Chairman, Department of Urology, and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center, Dr. Samadi’s robotic prostate removal surgery is one of the most effective prostate cancer treatment options available. Using his custom SMART (Samadi Modified Advanced Robotic Technique) surgery he has successfully removed over 4,000 cancerous prostates. Read the full extract here.

So, there are lots of expectations that this test will improve personalized Prostate cancer treatment for men. More support should be provided so that this test could be validated. It is important to mention that this new test could bring about less invasive, less rigorous and less painful diagnostic methods. Hence, men can now be saved from that entire trauma.

Finally, Dr.Samadi applies a less invasive approach to remove prostate gland affected by cancer. This new test can be said to be inline with he does to provide better treatments for men.

Here Is Your Medical Team for Prostate Cancer Treatment

If you are living with prostate cancer, you may need a team of medical specialists to get the best treatments and possible have your life extended. Each member or the groups have important roles they play to ensure you are provided with the very best care.

If you don’t really know who are the primary members of the group, this article is written provide you some useful details. It describes some of the primary members of the medical team that would treat your prostate cancer.

The Urologist – This is a doctor that specializes in the treatment of diseases affecting the urinary system. Since the prostate gland is located near the urinary system in men, cancerous cells on it often affects the passing of urine. The urologist uses his surgical experience to diagnose and treat prostate cancer affecting the urinary system.

In most cases, this medical specialist is invaluable to help deal with advanced prostate cancer. The treatments offered by this specialist will include surgical removal of the prostate gland and prescription endocrine therapy. In some cases, the urologist can refer you to other specialists of particular aspects of cancer of the prostate.

The Oncologist – This is the doctor that specializes in the diagnoses and treatment of tumor in the body. Hence, there is no other that is qualified to treat cancer of the prostate than this specialist. The Oncologist can still specialize in the different treatment aspect radiation therapy, chemotherapy, hormonal therapy, radical prostatectomy, and other treatments to stop the growth and spread of malignant tumors or cancerous cells from the prostate gland.

In the course of your treatment for prostate cancer, the oncologist is a primary member of your medical team. You really cannot do any treatment without his involvement.

Apart from the Urologist and Oncologist, other important members of the medical team for the treatment of prostate cancer include: a physical therapist, a dietician, a social worker, and a laboratory scientist. All of these specialists, play important roles to see that you are treated very well of your prostate cancer condition.

Conclusively, it is important that you know members of the team that is helping you to get treated of any stage of prostate cancer. This will help you get relevant information in due course, More so, it is also important that you ensure that all members of the team are working hand in hand to provide you with safe and effective treatment.

Study of DNA Blood Test For Prostate Cancer Is Promising

Many men could be spared the rigors of invasive prostate cancer test if the result of a present study in the University of Pittsburgh is validated. The study has been ongoing and  it wants to indicate investigate whether prostate cancer aggressiveness and relapse can be predicted by DNA blood test.

Genetic abnormalities are often associated with prostate cancer cells and samples from such cells and normal cells were taken for the study. So far, the result has shown that relapse and aggressive prostate cancer can be predicted to some degree. Various blood samples and tissues were used in the study as highlighted below:

A blood test for men with prostate cancer could indicate whether their cancer is likely to recur after treatment, and if so, how aggressively, say researchers from the University of Pittsburg School of Medicine, USA.

A study to investigate whether prostate cancer relapse can be predicted by looking at genetic abnormities using tissue samples from tumours as well as from neighbouring tissues and blood samples had promising results. It could mean that less invasive tests could be used after a patient’s initial treatment to see if further treatment is needed. Patients could be spared further aggressive treatments if their cancer is found to be slow-growing and therefore unlikely to cause death.

Dr Jianhua Luo and his colleagues analysed the genomes of 104 prostate tumour samples, 85 blood samples and 49 samples of benign prostate tissue adjacent to tumours to identify copy number variations (CNVs). A CNV represents an abnormal number of copies of one or more sections of DNA. Samples from all three tissue/blood groups showed CNVs, some with similar deletion and amplification patterns. Using this data, the researchers were able to build a prediction model to identify patients at risk of relapse.

The researchers found that CNVs from prostate tumour tissue could predict the chance of relapse with significant accuracy, at 73 percent. Similarly, CNVs from these tissues could predict cancer aggression with 75 percent accuracy – although as the study was conducted in patients who had already undergone the removal of all or part of the prostate, the test did not identify benign tumours from aggressive ones before treatment.

Blood samples also had high predictive accuracy – at 81 percent for relapse and 69 percent for aggression; as did neighbouring benign prostate tissue samples – at 67 percent for relapse and 77 percent for aggression.

‘For a patient already having a radical prostatectomy, CNV analysis on the tumour or blood sample may help to decide whether additional treatment is warranted to prevent relapse. Despite some limitations, including the need for high quality genome DNA, CNV analysis on the genome of blood, normal prostate, or tumour tissues holds promise to become a more efficient and accurate way to predict the behaviour of prostate cancer’, said Dr Luo.

Reporting on the study, the Daily Mail said a blood test is likely to be several years away. The results of the study will need to be validated with further research and an inexpensive blood test developed before such a test could reach the market. Source.

So, with the information highlight above, it may become possible that men who have been subjected to various forms of tests for prostate cancer would now opt for a better option. They may now go for the DNA test, which would be less invasive. In addition, if the result of this study is validated, men with prostate cancer should now expect easy diagnosis and faster treatment of their condition.

Finally, this blood test can still be less expensive, thereby helping patients to save their lives and at the same time save their money. The authorities concerned should look into this study to see if quicker validation can be made since it shows lots of promises to victims and health care providers.

Next Page »